"In this HBV-HIV cohort of adults with high prevalence of tenofovir use, several biomarkers of renal function and bone turnover indicated worsening status over approximately 4 years, highlighting the ...

Use of tenofovir alafenamide fumarate (TAF) for HIV pre-exposure prophylaxis (PrEP) was associated with an increased risk of hypertension and the initiation of statin use within 2 years compared with ...

Pills for Pre-Exposure Prophylaxis (PrEP) to prevent HIV with PrEP acronym engraved Researchers sought to evaluate the risk for incident hypertension and statin initiation among patients receiving ...

For decades, HIV sufferers were bereft of effective treatment. In 2001, five years after their tenofovir disoproxil fumarate (TDF) drugs were patented, Gilead Pharmaceuticals received FDA approval, ...

Patients with HIV who switched to a treatment regimen that included tenofovir alafenamide (TAF) showed improvement in serum markers for hepatic steatosis (HS) among other benefits. Antiretroviral ...